Basetrophy Group Holdings Limited released its Monthly Return for the period ended 30 September 2026, confirming that both authorised and issued share capital remained unchanged during the month.
Authorised Share Capital • The company’s authorised share capital was steady at 3.00 billion ordinary shares with a par value of HKD 0.10 each, translating to HKD 300.00 million in registered capital. • No increases or reductions were recorded.
Issued and Treasury Shares • Issued shares (excluding treasury shares) closed the month at 265.61 million, identical to the previous month’s balance. • The company held no treasury shares, and there were no share repurchases, cancellations, or new issues.
Equity Instruments and Capital-Raising Activities • No share options were outstanding, granted, exercised, or cancelled under the 7 June 2017 Share Option Scheme. • The company reported no warrants, convertible securities, or other equity-linked instruments, and no funds were raised from equity issuance during the month.
Public Float Compliance • Basetrophy Group affirmed compliance with the Hong Kong Stock Exchange’s minimum public float requirement of 25% for the reporting class of shares.
Governance Confirmation • Chairman and Executive Director Mr Chan Kui Ming confirmed that all regulatory and listing rule obligations were observed during the period, and no discrepancies were identified in the company’s share capital disclosures.
The unchanged figures underscore a period of stability in Basetrophy Group’s capital structure with full adherence to Hong Kong listing regulations.
Comments